NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.

CompletedN/A

Sponsor: Pfizer

Conditions: Migraine

Countries: United States

The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024. Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migraine preventive medications) and completed a survey were eligible for this study. Acute treatment is a short-term treatment. The aim of this retrospective analysis was to learn about the user´s satisfaction with Nurtec or the triptan. The level of satisfaction with Nurtec will be compared to the level of satisfaction with triptans. The benefit of this study is the real-life setting of the information collected. This means that the users were using the Migraine Buddy app for tracking their migraines in real life.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migraine preventive medications).
* Male or female participants with migraine
* Having consented to the anonymous use of their data for research
* Currently using Nurtec and/or triptans to treat migraine attacks

Exclusion Criteria:

* Users who did not report using either medication for which they complete the survey within 60 days prior to the survey.

Locations (1)

New York, New York, United States